Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells

25 Aug 2021

Abstract excerpt

The piggyBac transposon system provides a non-viral alternative for cost-efficient and simple chimeric antigen receptor (CAR) T cell production. The generation of clinical-grade CAR T cells requires strict adherence to current good manufacturing practice (cGMP) standards. Unfortunately, the high costs of commonly used lentiviral or retroviral vectors limit the manufacturing of clinical-grade CAR T cells in many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34631931
DOI: 10.1016/j.omtm.2021.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cellsPMID 34631931Read ↗

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read ↗

CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking RegionsSemantic proximity Read ↗

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection.Semantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancesSemantic proximity Read ↗

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesSemantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T LymphocytesSemantic proximity Read ↗

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T CellsSemantic proximity Read ↗

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity Read ↗

The Past, Present, and Future of Non-Viral CAR T CellsSemantic proximity Read ↗

<i>Quantum CART</i> ( <i>qCART</i> ), a <i>piggyBac-based</i> system for development and production of virus-free multiplex CAR-T cell therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.